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The combination of degradable starch microspheres and angiotensin II in
the manipulation of drug delivery in an animal model of colorectal
metastasis
R. Carter, T.G. Cooke, D. Hemingway, C.S. McArdle & W. Angerson
University Department ofSurgery, Glasgow Royal Infirmary, Castle Street, Glasgow, UK.
Summary Both biodegradable emboli and pharmacological agents can enhance regional therapy for hepatic
targeting. Using a rat model with similar haemodynamic characteristics to human colorectal liver tumour and
a radio-labelled marker of similar molecular weight to Adriamycin, we have combined the two approaches to
see if the effect was addictive.
Following induction ofliver tumour in male hooded rats by intrahepatic injection of HSN sarcoma cells, the
relative distribution of marker, 99mTc methylene diphosphonate (MDP), was studied in three groups given the
following by injection into the hepatic artery.
(1) Saline (Control) + MDP;
(2) Degradable Starch Microspheres (DSM) + MDP; and
(3) Angiotensin 11+ DSM + MDP.
Both Degradable Starch Microspheres alone (P <0.001) and Degradable Starch Microspheres + Angioten-
sin II (P = 0.003) significantly increased the retention of marker in liver and tumour at I min following
injection, with a 12-fold improvement over controls, but the tumour:liver ratio was unaltered. By 90 min the
MDP levels in normal hepatic parenchyma had returned to control values. There was relatively less washout
with significant retention in tumour tissue in both DSM (P = 0.03) and combination treated animals
(P = 0.001), with a significantly improved (P = 0.001) tumour to liver ratio (5.22:1) in combination treated
animal relative to those treated with DSM alone.
Recent advances in chemotherapeutic treatment in patients
with colorectal carcinoma either given in the presence of
established metastases (Kemeny et al., 1987; Erlichman et al.,
1988; Poon et al., 1989) or as an adjuvant treatment (Windle
et al., 1987; Taylor et al., 1985; Moertel et al., 1990), have
resulted in both objective responses and small increases in
survival. Regional chemotherapy aims to increase drug
delivery to hepatic tumours and at the same time reduce
systemic side effects. Hepatic arterial infusion is based on the
rationale that the blood supply to hepatic metastases is
derived principally from the hepatic artery with little contri-
bution from the portal vein (Ensminger et al., 1978; Sigard-
son et al., 1986). This approach has been associated with
objective therapeutic responses, but has not yet resulted in an
improvement in survival over systemic therapy in controlled
clinical trials (Kemeny et al., 1987). One possible explanation
for the failure of regional therapy to improve survival is that
many colorectal metastases are relatively hypovascular, the
blood supply favouring delivery of drug to normal hepatic
parenchyma.
Numerous vasoactive drugs have been used to manipulate
hepatic and tumour blood flow and we have previously
reported the effects of phenylephrine and angiotensin II on
the distribution of a radio-labelled low molecular weight
marker, 99ITc methylene diphosphonate (MDP), in an animal
model (Hemingway et al., 1990). We observed up to a 4-fold
increase in the retention of marker in the tumour tissue
relative to normal hepatic parenchyma at 1 min after injec-
tion. However, the vasoconstriction response was transitory
and there was significant 'washout' of marker by 90 min. We
have also used degradable starch microspheres (DSM) to
manipulate drug delivery, and found a similar 4-fold reten-
tion in tumour at 1 min, but with less 'washout' at 90 min
(Cooke et al., 1990).
It is possible that these pharmacological and physical
methods of enhancing second order targeting to liver tumour
may act additively, and we report a series ofexperiments that
have investigated this hypothesis.
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Materials and methods
Animal model
Liver tumours were induced in male Hooded Lister rats,
weight 200-250 g, by a sub capsular injection of 106 HSN
sarcoma cells. Three seeks after inoculation, overt liver
tumours, weighing approximately 1-2 g, had developed at
the sites of injection. Previous evaluation of the
haemodynamic characteristics of this tumour model has
shown that its blood supply is derived, as in metastatic
colorectal tumours, almost entirely from the hepatic artery,
the portal contribution being minimal. These tumours are
relatively hypovascular compared to the surrounding normal
liver with a tumour: liver hepatic arterial blood flow ratio of
0.6:1 (Hemingway et al., 1990).
Tumour-bearing rats were anaesthetised by an intra-
peritoneal injection of sodium pentobarbitone (Sagatal
30 mgkg-1), and the gastroduodenal artery was cannulated.
Care was taken to ensure that the tip of the cannula lay at
the junction of the coeliac and hepatic arteries. A trial injec-
tion of saline ensured that the injectate flowed along the
hepatic artery and not in a retrograde manner down the
coeliac artery. The right common carotid artery was then
cannulated for continuous measurement of systemic arterial
blood pressure via a strain gauge transducer driving a pen
recorder (Gould Medical, Lutterworth, UK).
Bloodflow manipulation
A Pilot study (of three animals per group) compared:
(a) DSM followed by angiotensin II and MDP; or
(b) angiotensin II followed by DSM and MDP;
(c) DSM, angiotensin II and MDP given simultaneously,
was performed to ascertain the most effective mode of
administration.
The results of this study suggested that the most effective
combination was achieved by the slow bolus injection of
Angiotensin II, followed 1 min later by degradable starch
microspheres (2 mg) and 30 lsl of MDP given over 30 s. This
schedule was therefore used in the main comparative study.
(Figure 1).
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Figure 1 Pilot study comparing alternative sequences of delivery
in combination animals. Results at 90 min expressed as median
% of the injected dose per gram of tissue.
Study design
Three experimental groups receiving regional delivery of 9'Tc
labelled methylene diphosphonate (MDP), 100 MBq ml-',
were compared.
Control animals (two groups of nine) received in intra-
arterial injection of 30 of MDP in physiological saline over
30s. Two groups of animals (n = 12) were given a 20 IA
intra-arterial injection of degradable starch microspheres
(100 mg ml') mixed with 30 slI of 9'9Tc MDP as previously
described (Cooke et al., 1990).
In two further groups of experimental animals (12 per
group) 50 gAl of angiotensin II (5 gsg ml-1) (Ciba-Geigy), was
injected into the gastroduodenal artery over 30 s (Hemingway
et al., 1990). Systemic arterial blood pressure was monitored
and one animal was rejected from further analysis when a
rise in mean arterial pressure did not occur. One minute
later, an injection of degradable starch microspheres (2 mg)
with 30 plA of 9'Tc MDP was performed.
Animals were sacrified 1 and 90 min following injection.
The tumour tissue was carefully dissected from the surround-
ing normal liver tissue and divided into lobes to ensure that
there was no intrahepatic distribution variation. The tissue
was divided, weighed and placed in vials for immediate count-
ing in a well gamma counter. A reference sample (30 ,ul) of
the 99"Tc MDP was taken at the time of the hepatic injection
and counted prior to the samples. Counts were corrected for
decay of the 'Tc.
Statistical analysis
The results have been expressed both as a percentage of the
injected dose per gram oftissue, and as a ratio of the relative
counts detected in tumour and normal liver tissue. The
significance of the observed differences were assessed using
the Kruskal-Wallis analysis of varience, Mann-Whitney U
test and Wilcoxon signed ranks test as appropriate.
Results
Comparison of the three study groups using the Kruskal-
Wallis test confirmed that there was a significant difference in
retention of marker in tumour (P = 0.003) and liver
(P <0.001) at 1 min but only in tumour (P <0.001) and not
liver (P = 0.21) by 90 min. Whereas there was no significant
difference in the tumour:liver ratio at 1 min (P = 0.87) there
was a significant difference by 90 min (P = 0.001). The
results are summarised and detailed below in Table 1. All
results are expressed as the median (and range) of the percent-
age injected dose per gram of tissue.
Uptake at one minute
There was significantly increased retention of marker in liver
and tumour tissue in both DSM and combination groups over
controls at 1 min. The tumour to liver ratios were however
unchanged and there was no difference in the retention of
marker between DSM and combination groups.
Uptake at 90 minutes
In normal liver tissue washout of marker resulted in levels
returning to control values by 90 min in both treatment
groups. There was relatively less washout from tumour tissue
with increased tumour to liver ratios, more marked in com-
bination animals (5.22:1) than DSM animals (2.09:1). The
absolute retention of marker was also significantly greater in
combination animals than those treated with DSM alone.
Bloodpressure
In animals treated with Angiotensin II the pre-treatment
median systolic blood pressure was 114 mmHg (106-120).
Following injection of angiotensin II there was a rise in
median systolic pressure to 131 mmHg (120-143).
Discussion
Despite the accumulating clinical experience in the manipula-
tion ofhepatic arterial blood flow to optimise regional delivery





Liver 0.08 (0.01-0.62) 0.94 (0.73-1.18) 0.95 (0.4-1.01)
****
Tumour 0.06 (0.01-0.4) 0.71 (0.09-4.55) 0.52 (0.16-1.9)
T/L Ratio 0.72 (0.1-6.2) 0.69 (0.1-4.2) 0.72 (0.2-2.2)
90 Minutes
Liver 0.07 (0.05-0.16) 0.12 (0.04-0.89) 0.11 (0.03-0.24)
*** ~**X$ Tumour 0.04 (0.01-0.08) 0.19 (0.06-0.75) 0.53 (0.15-1.09)
T/L Ratio 0.49 (0.2-1.1) 2.09 (0.1-3.6) 5.22 (1.9-11.4)
Results are expressed as the median percentage of the injected dose per gram of
tissue, the range in parenthesis.
DSM or DSM/AII vs control (Mann-Whitney): *P <0.05, **P <0.01, ***P <0.001.
DSM/ALL vs DSM: ItP<0.01, ttt P<0.001.
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to tumour tissue, the rationale for using degradable emboli or
vasoactive agents for regional tumour targeting has not been
fully evaluated at an experimental level. Tumour vessels are
immature and, lacking muscular elements, are therefore unable
to react to vasoconstricting agents (Mattson et al., 1977; Matt-
son et al., 1978). Any response therefore occurs predominantly
in the normal hepatic parenchyma inducing a temporary
relative tumour hypervascularity favouring the delivery of
administered agent to tumour rather than normal liver.
Using the HSN sarcoma cell model of colorectal metastases
we have previously shown that both phenylephrine and
angiotensin II will increase the delivery of marker to tumour
4-fold over controls although the effect is transitory (Heming-
way et al., 1990). This study has also confirmed our previous
report that DSM can significantly increase the retention of
marker within tumour (Cooke et al., 1990). All animals
studied had on average a 12-fold increase in retention of
marker compared to controls at 1 min after injection. In con-
trast to our earlier reported studies we have failed to confirm
an immediate preferential delivery to hepatic tumour. We
previously suggested that the increased retention of marker
was due to a redistribution ofintrahepatic blood diverting flow
marker away from normal hepatic parenchyma towards
hepatic tumour. The results from this study however would
suggest that the DSM is distributed according to blood flow
which initially results in a similar tumour to liver ratio as
control animals. The relatively greater retention within tumour
tissue, with almost complete washout of marker from normal
liver tissue at 90 min, is probably the result ofcontinued portal
washout in normal hepatic parenchyma, which is not present
in tumour.
Angiotensin II results in redistribution of intrahepatic
arterial flow towards tumour tissue (Hemingway et al., 1990).
In this experiment the administration of Angiotensin II
immediately prior to the regional injection of DSM may
therefore result in preferential delivery of both DSM and
marker to tumour tissue. Whilst there was no immediate
advantage for the combination of DSM and angiotensin II
over DSM alone, there was an advantage at 90 min with
significantly greater retention ofmarker in tumour tissue com-
pared to DSM alone and a 12-fold increase compared to the
value in control animals. Moreover, the tumour:liver ratio of
retained marker was significantly improved using combined
angiotensin II and DSM with a concentration of marker in
tumour over five times that in normal hepatic parenchyma.
The maintenance of relatively high marker concentration in
tumour over a 90 min period may reflect blood flow stasis and
further prevention of washout, due to targeting of the DSM
toward the tumour by the Angiotensin II.
Both Angiotensin II and DSM have been used indepen-
dently to improve regional delivery of chemotherapeutic drugs
in clinical trials in patients with colorectal metastases (Civellari
et al., 1985; Goldberg et al., 1990; Hunt et al., 1990). The
results of this study would suggest that a combination of
Angiotensin II and DSM may further improve the delivery of
drug to hepatic tumour, whilst minimising exposure of normal
hepatic parenchyma to potentially hepatotoxic drugs.
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